BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22008853)

  • 21. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
    Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
    ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
    Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
    Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
    Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
    Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
    Dilly AK; Song X; Zeh HJ; Guo ZS; Lee YJ; Bartlett DL; Choudry HA
    Transl Res; 2015 Oct; 166(4):344-54. PubMed ID: 25890193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.
    Heald RA; Jackson P; Savy P; Jones M; Gancia E; Burton B; Newman R; Boggs J; Chan E; Chan J; Choo E; Merchant M; Rudewicz P; Ultsch M; Wiesmann C; Yue Q; Belvin M; Price S
    J Med Chem; 2012 May; 55(10):4594-604. PubMed ID: 22506516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MEK inhibitor for gastric cancer with MEK1 gene mutations.
    Sogabe S; Togashi Y; Kato H; Kogita A; Mizukami T; Sakamoto Y; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Tomida S; Yasuda T; Takeyama Y; Okuno K; Nishio K
    Mol Cancer Ther; 2014 Dec; 13(12):3098-106. PubMed ID: 25253779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
    Sini P; Gürtler U; Zahn SK; Baumann C; Rudolph D; Baumgartinger R; Strauss E; Haslinger C; Tontsch-Grunt U; Waizenegger IC; Solca F; Bader G; Zoephel A; Treu M; Reiser U; Garin-Chesa P; Boehmelt G; Kraut N; Quant J; Adolf GR
    Mol Cancer Ther; 2016 Oct; 15(10):2388-2398. PubMed ID: 27496137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.
    Falck Miniotis M; Arunan V; Eykyn TR; Marais R; Workman P; Leach MO; Beloueche-Babari M
    Cancer Res; 2013 Jul; 73(13):4039-49. PubMed ID: 23639941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
    Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
    Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
    Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
    Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K
    J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
    Yari H; Ganjalikhany MR; Sadegh H
    Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
    Hartung IV; Hammer S; Hitchcock M; Neuhaus R; Scholz A; Siemeister G; Bohlmann R; Hillig RC; Pühler F
    Bioorg Med Chem Lett; 2016 Jan; 26(1):186-93. PubMed ID: 26611920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
    Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
    Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.